Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5159]

Ganetespib in first-line treatment of women with metastatic HER2 positive or...

Prof David Cameron - Edinburgh Cancer Centre, Edinburgh, UK

Ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer ( Prof David Cameron - Edinburgh Cancer Centre, Edinburgh, UK )

Regular physical activity reduces breast cancer risk irrespective of age

Prof Mathieu Boniol - International Prevention Research Institute, Lyon, France

Regular physical activity reduces breast cancer risk irrespective of age ( Prof Mathieu Boniol - International Prevention Research Institute, Lyon, France )

Radiotherapy after mastectomy benefit for breast cancer that has spread to just...

Dr Paul McGale, Dr Carolyn Taylor, Dr Tim Whelan

Radiotherapy after mastectomy benefit for breast cancer that has spread to just a few lymph nodes ( Dr Paul McGale, Dr Carolyn Taylor, Dr Tim Whelan )

Biomarker development for ipilimumab and prostate GVAX treatment

Prof Tanja D. de Gruijl - VU University Medical Centre, Amsterdam, The...

Biomarker development for ipilimumab and prostate GVAX treatment ( Prof Tanja D. de Gruijl - VU University Medical Centre, Amsterdam, The Netherlands )

Immuno-biological properties of human cancer stem cells

Dr Cristina Maccalli - NIBIT (Italian Network for Biotherapy of Tumours), Siena...

Immuno-biological properties of human cancer stem cells ( Dr Cristina Maccalli - NIBIT (Italian Network for Biotherapy of Tumours), Siena, Italy )

Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer

Dr Christian Klein - Head of Oncology Programs, Discovery Oncology, Roche...

Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer ( Dr Christian Klein - Head of Oncology Programs, Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland )

ecancermedicalscience Editor's Choice for January 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience Editor's Choice for January 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Multiple Myeloma Debate 2014: Recent advances in multiple myeloma

Dr Pieter Sonneveld, Prof Michele Cavo, Dr Jesus San Miguel and Dr Meletios...

Multiple Myeloma Debate 2014: Recent advances in multiple myeloma ( Dr Pieter Sonneveld, Prof Michele Cavo, Dr Jesus San Miguel and Dr Meletios Dimopoulos )

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic...

Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases ( Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden )

Predictive power of PSA patterns during off-time treatment periods with...

Dr Rafael Sanchez-Salas - Institut Mutualiste Montsouris, Paris, France

Predictive power of PSA patterns during off-time treatment periods with intermittent androgen deprivation ( Dr Rafael Sanchez-Salas - Institut Mutualiste Montsouris, Paris, France )

Review of the latest abstracts from the COU-AA-302 trial

Dr Chris Parker and Prof Stephane Oudard

Review of the latest abstracts from the COU-AA-302 trial ( Dr Chris Parker and Prof Stephane Oudard )

Gleason score efficacy predictions in abiraterone acetate therapy with mCRPC

Dr Karim Fizazi - Institut Gustave Roussy, Paris, France

Gleason score efficacy predictions in abiraterone acetate therapy with mCRPC ( Dr Karim Fizazi - Institut Gustave Roussy, Paris, France )

More from ecancer